Hepatitis Clinical Trials in San Antonio

Showing 21-40 of 226 trials

Study of NGM282 in Patients With Nonalcoholic Steatohepatitis (NASH)

NCT02443116

The purpose of this study is to determine the safety, tolerability, and efficacy of NGM282 in patients with nonalcoholic steatohepatitis.

Nonalcoholic Steatohepatitis (NASH)

NGM Biopharmaceuticals, Inc254 participantsStarted Jul 2015

Chandler, Arizona, United States • Tucson, Arizona, United States • Los Angeles, California, United States +19 more locations

COMPLETEDPhase 2< 1 mile

A Study in Participants With Non-cirrhotic NASH With Fibrosis

NCT05638737

This is a randomized, double-blind, placebo-controlled, parallel-group, multicenter trial. Participants will be in the trial for up to 24 weeks, including a screening period lasting up to 8 weeks, a 12-week treatment period, and a 4-week safety follow-up period Participants are not expected to directly benefit from treatment during this trial. Participants will help researchers learn more about and how to develop AZD4831 to treat NASH.

Non-Cirrhotic Non-alcoholic Steatohepatitis With Fibrosis

AstraZeneca112 participantsStarted Oct 2022

Chandler, Arizona, United States • Tucson, Arizona, United States • Chula Vista, California, United States +62 more locations

Study of NGM282 in Patients With Nonalcoholic Steatohepatitis (NASH)

A Study in Participants With Non-cirrhotic NASH With Fibrosis

Hepatitis Trials in Other Cities

Ph 2 Study of the Safety and Efficacy of Three HU6 Dose Levels and Placebo in Nonalcoholic Steatohepatitis

LITMUS Imaging Study

DUET Study: A Clinical Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of Orally Administered TERN-501 as Monotherapy and in Combination With TERN-101 in Noncirrhotic Adults With Presumed Non-Alcoholic Steatohepatitis

A Phase 2b Study of Icosabutate in Fatty Liver Disease

Efficacy, Safety and Tolerability of the Combination of Tropifexor & Licogliflozin and Each Monotherapy, Compared With Placebo in Adult Patients With NASH and Liver Fibrosis.

Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment

A Research Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of DUR-928 in Patients With Alcoholic Hepatitis

A Study of the Safety and Tolerability of LPCN 1144 in Subjects Who Completed the LPCN 1144-18-002 Trial

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of BFKB8488A Compared With Placebo in Participants With Non-Alcoholic Steatohepatitis

A Phase I Pharmacokinetic Study of TVB-2640 (Denifanstat) in Subjects With Mild, Moderate, or Severe Hepatic Impairment Compared to Subjects With Normal Hepatic Function

HCV-TARGET- Hepatitis C Therapeutic Registry and Research Network

A Study of Different Combination Regimens Including JNJ-73763989 and/or JNJ-56136379 for the Treatment of Chronic Hepatitis B Virus Infection

Study of Sequential GSK3228836 and Peginterferon Treatment in Participants With Chronic Hepatitis B (CHB)

A Study of Sequential Therapy With Daplusiran/Tomligisiran (DAP/TOM) Followed by Bepirovirsen in Participants Living With Chronic Hepatitis B (CHB)

A Study of JNJ-73763989, Pegylated Interferon Alpha-2a, Nucleos(t)Ide Analog (NA) With or Without JNJ-56136379 in Treatment-naive Participants With Hepatitis B e Antigen (HBeAg) Positive Chronic Hepatitis B Virus (HBV) Infection

Study of IMC-I109V in Non-cirrhotic HBeAg-negative Chronic HBV Infection

Treatment Outcomes in Chronic Hepatitis B Patients on Sequential Therapy With Tenofovir Alafenamide (TAF)

A Study of JNJ-73763989 + Nucleos(t)Ide Analog in Participants Co-Infected With Hepatitis B and Hepatitis D Virus

Other Conditions in San Antonio